Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS